Apogee Therapeutics, Inc. (APGE) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Apogee Therapeutics, Inc. (APGE) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Apogee Therapeutics, Inc. (Stock Symbol: APGE)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
a growing mid-cap opportunity with strong fundamentals.
Financial Performance & Key Metrics Analysis
Market Capitalization: $2241 million - Classified as a
mid-cap growth stock with balanced risk-reward profile.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Apogee Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Apogee Therapeutics, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share
.
.
Apogee Therapeutics, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Apogee Therapeutics, Inc. interactive price chart and technical analysis...
Deep dive into Apogee Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Apogee Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Apogee Therapeutics, Inc.: With a P/E ratio of -20.51, the market sees the stock as potentially undervalued.
P/E Ratio-20.51x
P/B Ratio4.25x
Market Cap$2241M
EPS$-4.14
Book Value/Share$13.65
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Apogee Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Apogee Therapeutics, Inc.:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Apogee Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Apogee Therapeutics, Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Apogee Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Apogee Therapeutics, Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Apogee Therapeutics, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Apogee Therapeutics, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Apogee Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Apogee Therapeutics, Inc.:
Income Statement ($ Millions)
R&D Expense$125M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding59M
Growth Metrics (YoY)
EPS Growth-5.4%
Apogee Therapeutics, Inc. (APGE) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Apogee Therapeutics, Inc. stock analysis.
Loading fundamental data...
Loading Apogee Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...
Latest Apogee Therapeutics, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Apogee Therapeutics, Inc. (APGE) stock price and investment outlook.
We recently compiled a list of 11 Best Future Stocks to Buy Now. Apogee Therapeutics, Inc. stands fourth on our list. Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotech company ...
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics ...
SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated ...
Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD ...
Apogee Therapeutics, Inc., a clinical-stage biotechnology company focused on advancing novel biologics for inflammatory and immunology markets, has announced it will share interim results from its ...
APG777 represents the first clinical-stage product candidate from the company’s strategic collaboration with Paragon Therapeutics, Inc., an innovative discovery engine for biologics. About Apogee ...
Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat reports.
Apogee Therapeutics, Inc. has a 1-year low of $29.10 and a 1-year high of $63.50. The business has a 50-day moving average price of $37.06 and a 200 day moving average price of $45.25.
SAN FRANCISCO and WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic ...
Apogee Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Apogee Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Apogee Therapeutics, Inc. Stock Forecast
How accurate are Apogee Therapeutics, Inc. stock predictions?
Our AI model demonstrates 32% historical accuracy for APGE predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Apogee Therapeutics, Inc. stock price forecasts?
Is Apogee Therapeutics, Inc. a good investment in 2025?
Based on our AI analysis, Apogee Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Apogee Therapeutics, Inc. forecasts updated?
Apogee Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Apogee Therapeutics, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Apogee Therapeutics, Inc. stock.
